Search

Your search keyword '"Traynor, Anne"' showing total 454 results
Start Over Author "Traynor, Anne"
454 results on '"Traynor, Anne"'

52. Examining the Instructional Sensitivity of Constructed-Response Achievement Test Item Scores.

Author

Traynor, Anne, Li, Cheng-Hsien, and Zhou, Shuqi

Subjects
*ACHIEVEMENT tests, *MASTER teachers, *SCORING rubrics, *TEST validity, *SCIENCE teachers
Abstract

Inferences about student learning from large-scale achievement test scores are fundamental in education. For achievement test scores to provide useful information about student learning progress, differences in the content of instruction (i.e., the implemented curriculum) should affect test-takers’ item responses. Existing research has begun to identify patterns in the content of instructionally sensitive multiple-choice achievement test items. To inform future test design decisions, this study identified instructionally (in)sensitive constructed-response achievement items, then characterized features of those items and their corresponding scoring rubrics. First, we used simulation to evaluate an item step difficulty difference index for constructed-response test items, derived from the generalized partial credit model. The statistical performance of the index was adequate, so we then applied it to data from 32 constructed-response eighth-grade science test items. We found that the instructional sensitivity (IS) index values varied appreciably across the category boundaries within an item as well as across items. Content analysis by master science teachers allowed us to identify general features of item score categories that show high, or negligible, IS. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

53. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study

Author

Bible, Keith C, Suman, Vera J, Molina, Julian R, Smallridge, Robert C, Maples, William J, Menefee, Michael E, Rubin, Joseph, Sideras, Kostandinos, Morris, John C, III, McIver, Bryan, Burton, Jill K, Webster, Kevin P, Bieber, Carolyn, Traynor, Anne M, Flynn, Patrick J, Goh, Boon Cher, Tang, Hui, Ivy, Susan Percy, and Erlichman, Charles

Published
2010
Full Text
View/download PDF

58. A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non–small cell lung cancer previously treated with a PD‐1 or PD‐L1 inhibitor: Big Ten Cancer Research Consortium BTCRC‐LUN15‐029.

Author

Salous, Tareq, Shukla, Nikhil A., Althouse, Sandra K., Perkins, Susan M., Furqan, Muhammad, Leal, Ticiana, Traynor, Anne M., Feldman, Lawrence E., Hanna, Nasser H., and Durm, Greg A.

Subjects
NON-small-cell lung carcinoma, PROGRAMMED cell death 1 receptors, PROGRAMMED death-ligand 1, CANCER research, SQUAMOUS cell carcinoma
Abstract

Background: Immunotherapy using a checkpoint inhibitor (CPI) alone or in combination with chemotherapy is the standard of care for treatment‐naive patients with advanced non–small cell lung cancer (NSCLC) without driver mutations for which targeted therapies have been approved. It is unknown whether continuing CPI treatment beyond disease progression results in improved outcomes. Methods: Patients who experienced progressive disease (PD) after a clinical benefit from chemotherapy plus a CPI were enrolled. Patients received pembrolizumab (200 mg every 3 weeks) plus next‐line chemotherapy. The primary end point was progression‐free survival (PFS) according to the Response Evaluation Criteria in Solid Tumors (version 1.1). Key secondary end points included the overall survival (OS), clinical benefit rate, and toxicity. The authors' hypothesis was that continuing pembrolizumab beyond progression would improve the median PFS to 6 months in comparison with a historical control of 3 months with single‐agent chemotherapy alone. Results: Between May 2017 and February 2020, 35 patients were enrolled. The patient and disease characteristics were as follows: 51.4% were male; 82.9% were current or former smokers; and 74.3%, 20%, and 5.7% had adenocarcinoma, squamous cell carcinoma, and NSCLC not otherwise specified, respectively. The null hypothesis that the median PFS would be 3 months was rejected (p <.05). The median PFS was 5.1 months (95% confidence interval [CI], 3.6–8.0 months). The median OS was 24.5 months (95% CI, 15.6–30.9 months). The most common treatment‐related adverse events were fatigue (60%), anemia (54.3%), and nausea (42.9%). There were no treatment‐related deaths. Conclusions: Pembrolizumab plus next‐line chemotherapy in patients with advanced NSCLC who experienced PD after a clinical benefit from a CPI was associated with statistically significant higher PFS in comparison with historical controls of single‐agent chemotherapy alone. Pembrolizumab plus next‐line chemotherapy in patients with advanced non–small cell lung cancer who experienced progressive disease after a clinical benefit from a checkpoint inhibitor was associated with statistically significant higher progression‐free survival in comparison with a historical control of single‐agent chemotherapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

71. A Multicenter Phase 2 Trial of Pazopanib in Metastatic and Progressive Medullary Thyroid Carcinoma: MC057H

Author

Bible, Keith C., Suman, Vera J., Molina, Julian R., Smallridge, Robert C., Maples, William J., Menefee, Michael E., Rubin, Joseph, Karlin, Nina, Sideras, Kostandinos, Morris, John C., III, McIver, Bryan, Hay, Ian, Fatourechi, Vahab, Burton, Jill K., Webster, Kevin P., Bieber, Carolyn, Traynor, Anne M., Flynn, Patrick J., Cher Goh, Boon, Isham, Crescent R., Harris, Pamela, and Erlichman, Charles

Published
2014

75. Outcomes and safety analysis of a phase IB trial of stereotactic body radiotherapy (SBRT) to all sites of oligometastatic non-small cell lung cancer combined with durvalumab and tremelimumab.

Author

Bassetti, Michael Frederick, primary, Sethakorn, Nan, additional, Lang, Joshua Michael, additional, Schehr, Jennifer L., additional, Schultz, Zachery, additional, Morris, Zachary Scott, additional, Matkowskyj, Kristina A., additional, Eickhoff, Jens C., additional, Morris, Brett, additional, Traynor, Anne M., additional, Duma, Narjust, additional, Campbell, Toby Christopher, additional, Baschnagel, Andrew, additional, and Leal, Ticiana, additional

Published
2021
Full Text
View/download PDF

78. Measuring students’ learning progressions in energy using cognitive diagnostic models.

Author

Shuqi Zhou and Traynor, Anne

Subjects
MASTERY learning, ENERGY consumption, PHYSICAL sciences, LEARNING, STUDENTS
Abstract

This study applied cognitive diagnostic models to assess students’ learning progressions in energy. A Q-matrix (i.e., an item attribute alignment table) was proposed based on existing literature about learning progressions of energy in the physical science domain and the Trends in International Mathematics and Science Study (TIMSS) assessment framework. The Q-matrix was validated by expert review and real data analysis. Then, the deterministic inputs, noisy ‘and’ gate (DINA) model with hierarchical relations was applied to data from three jurisdictions that had stable, defined science curricula (i.e., Australia, Hong Kong, and Ontario). The results suggested that the hypothesized learning progression was consistent with the observed progression in understanding the energy concept. We also found similarities in students’ attribute mastery across the three jurisdictions. In addition, we examined the instructional sensitivity of the selected item. We discuss several curriculum-related issues and student misconceptions that may affect students’ learning progressions and mastery patterns in different regions of the world. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

93. An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer.

Author

Bible, Keith C., Menefee, Michael E., Lin, Chia-Chi (Josh), Millward, Michael J., Maples, William J., Goh, Boon Cher, Karlin, Nina J., Kane, Madeleine A., Adkins, Douglas R., Molina, Julian R., Donehower, Ross C., Lim, Wan-Teck, Flynn, Patrick J., Richardson, Ronald L., Traynor, Anne M., Rubin, Joseph, LoRusso, Patricia M., Smallridge, Robert C., Burton, Jill K., and Suman, Vera J.

Subjects
IODINE isotopes, FISHER exact test, THYROGLOBULIN, IMMUNOGLOBULINS, SALVAGE therapy, THYROIDITIS
Abstract

Introduction: Multikinase inhibitors have clinical activity in radioactive iodine refractory (RAIR) differentiated thyroid cancers (DTCs) but are not curative; optimal management and salvage therapies remain unclear. This study assessed clinical effects of pazopanib therapy in RAIR-DTC patients with progressive disease, examining in parallel biomarker that might forecast/precede therapeutic response. Methods: Assessment of responses and toxicities and of any association between thyroglobulin (Tg) changes cycle 1 and RECIST (response evaluation criteria in solid tumors) response to pazopanib therapy were prospectively undertaken in Tg antibody negative RAIR-DTC patients. RECIST progressive metastatic disease <6 months preceding enrollment was required. With a sample size of 68 (assuming 23 attaining partial response [PR]), there would be 90% chance of detecting a difference of >30% when the proportion of patients attaining PR whose Tg values decrease by >50% is >50% cycle 1 (one-sided α = 0.10, two sample test of proportions). Mean corpuscular volume (MCV) change or mutational status or pretreatment were also explored as early correlates of eventual RECIST response. Results: From 2009 to 2011, 60 individuals were treated and evaluated; (one additional patient withdrew; another was found ineligible before therapy initiation); 91.7% had previous systemic therapy beyond RAI. Adverse events included one death (thromboembolic) deemed possibly pazopanib associated. Twenty-two confirmed RECIST PRs resulted (36.7%, confidence interval; CI [24.6–50.1]); mean administered 4-week cycles was 10. Among 44 fully accessible patients, the Tg nadir was greater among the 20 attaining PR (median: −86.8%; interquartile range [IQR]: −90.7% to −70.9%) compared with the 28 who did not (median: −69.0%; IQR: −78.1% to −27.7%, Wilcoxon rank-sum test: p = 0.002). However, the difference in the proportion of PRs among those whose Tg fell ≥50% after cycle 1 versus those that did not were not significantly correlated (−23.5% [CI: −55.3 to 8.3]; Fisher's exact test p-value = 0.27). RECIST response was also not correlated with/predicted by early MCV change, receipt of prior therapy, or tumor mutational status. Conclusions: This trial prospectively confirmed pazopanib to have clinical activity and manageable toxicities in patients with progressive RAIR-DTC. Response to pazopanib, however, was not robustly forecast by early associated changes in Tg or MCV, by prior therapy, or by tumor mutational status. ClinicalTrials.gov NCT00625846. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

97. Targeting Estrogen Receptor Beta in a Phase II Study of High Dose Estradiol in Metastatic Triple Negative Breast Cancer: A Wisconsin Oncology Network Study

Author

Wisinski, Kari B., Xu, Wei, Tevaarwerk, Amye J., Saha, Sandeep, Kim, KyungMann, Traynor, Anne, Dietrich, Leah, Hegeman, Robert, Patel, Dhimant, Blank, Jules, Harter, Josephine, and Burkard, Mark E.

Subjects
Adult, Aged, 80 and over, Estradiol, Administration, Oral, Estrogens, Triple Negative Breast Neoplasms, Middle Aged, Article, Disease-Free Survival, Drug Administration Schedule, Treatment Outcome, Wisconsin, Early Termination of Clinical Trials, Estrogen Receptor beta, Humans, Female, Molecular Targeted Therapy, Prospective Studies, Aged, Neoplasm Staging
Abstract

Estrogen receptor beta (ERβ) is expressed by 50% to 80% of triple-negative breast cancers (TNBC). Agonism of ERβ has antiproliferative effects in TNBC cells expressing ERβ. This phase 2 study evaluated single-agent high-dose estradiol in patients with advanced TNBC.Adult women with measurable advanced TNBC were treated with estradiol 10 mg oral 3 times daily provided continuously for 28-day cycles. A Simon optimal 2-stage design was used. The primary end point was objective response (OR). Secondary end points included progression-free survival (PFS), clinical benefit (CB), and safety. OR, CB, and PFS by ERβ status were also examined.Seventeen evaluable women were enrolled. Median age was 58 years (range, 34-90 years); the median number of prior systemic therapies was 2 (range, 0-6). One patient had a confirmed partial response (OR rate, 5.9%) and remained on the study for24 weeks. Three patients had stable disease, with one lasting more than 16 weeks. ERβ expression was detected in 77% (13 patients). The CB rate at 16 weeks was 15% (2 of 13) in ERβ-positive patients and 0% (0 of 4) in ERβ-negative patients (P = 1). PFS was poor (median, 1.9 months) and not statistically significantly different between ERβ-positive versus -negative patients. No new adverse events from estradiol were identified. The study closed after the first stage as a result of limited responses in these unselected patients.In unselected TNBC, high-dose estradiol has limited efficacy. However, further evaluation of ERβ selective agonists in TNBC selected by ERβ expression may be warranted.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results